reported as one of the systemic lesions of this autoimmune disease of unknownetiology (3) , and recent studies especially in the Japanese literature have emphasized its importance as a prognostic factor (4-7). There is a subgroup of patients with DMand a rapidly progressive ILD who have mild or even negligible muscle symptoms (amyopathic DM), mildly increased or normal levels of muscle enzymes, and negative antiJo-1 autoantibody (7). These patients often show intractable respiratory failure even if treated with a high dose or pulse therapy ofcorticosteroids and succumb to death within one year after the onset. Intravenous cyclophosphamide pulse therapy (CY Pulse) was first described for the treatment of refractory lupus nephritis (8) and was well tolerated with beneficial effect.
See also p 519.
There have been several reports that suggested effectiveness of this regimen for the treatment of ILD (9, 10). Al-Janadi et al (1 1) described 3 cases withPM/DMandILD who were successfully treated with CY pulse. However, the mechanism of how this regimenmaytake effect remains unclear. Recent reports have suggested that CD8-positive cytotoxic T cells may play an important role in the pathogenesis of PM ( 1 2), whereas infiltration of CD4-positive T cells or B cells around the microvasculature are found in DM,suggesting the role of humoral factormediated vascular injury ( 1 3). Our previous studies (4) showed that there was no detectable deposition of immunoglobulins or complement factors in lung specimens by immunohistology.
Wealso found that refractory cases with ILD showed mild or even minimal muscle symptomsand the muscle lesions themselves did respond well to steroid therapy. Therefore, it is probable that different immuneand inflammatory processes are responsible for muscle and lung lesions. Many of fatal cases died of respiratoy failure, and the chief findings of the lungs were diffuse alveolar damage (DAD). Little is known, however, about what kind of cells, cytokines or mediators are crucial in the development of this diffuse injury to the alveolar structures. CYpulse therapy should be considered as one of the choices for intractable cases with autoimmune diseases. However, it is often difficult to evaluate its effectiveness evenwhenthe cases are successfully treated, since conventional therapy as well as pulse therapy with corticosteroids are usually performed simultaneously with or before CYpulse, as in the case reported by Shinohara and associates in this issue of the Journal (14) . To address this question, it would be necessary to study a prospective trial (eg. steroid pulse along with conventional therapy versus steroids and additional CYpulse); such a study is now underway. Recent studies have also shown that cyclosporin, another potent T cell suppressant, might be useful for the control of this intractable lung disease (15 
